The new method designed by the team, described in the journal Science, identified these variants in the under-explored regions of DNA that do not code for proteins, but instead influence activity of other genes. As even more whole genome sequences become available, this approach can be applied to find any potential disease-causing variant in the non-coding regions of the genome…
"Although oral estrogens are effective for managing menopause symptoms, not enough is known about the cardiovascular safety of different oral hormone therapy products relative to each other," said first author Nicholas L. Smith, PhD. He is a professor of epidemiology at the UW School of Public Health, the director of the Veterans Affairs (VA) Seattle Epidemiologic Research and Information Center (ERIC) at the VA Puget Sound Health Care System, and an affiliate investigator at Group Health Research Institute. To further understand the differences in risk, the researchers also measured clotting (coagulation) factors in the blood of women who did not develop a clot. …
The researchers altered the amino acid sequence of a cystine knot peptide — or knottin — derived from the seeds of the squirting cucumber, a plant native to Europe, North Africa and parts of Asia. Peptides are short chains of amino acids that are integral to cellular processes; knottin peptides are notable for their stability and resistance to breakdown. The team used their invention as a "molecular flashlight" to distinguish tumors from surrounding healthy tissue. After injecting their bioengineered knottin into the bloodstreams of mice with medulloblastomas, the researchers found that the peptide stuck tightly to the tumors and could be detected using a high-sensitivity digital camera. …
"I think that most organic chemists had considered ingenol beyond the reach of scalable chemical synthesis," said TSRI Professor Phil S. Baran. Baran and his laboratory report their achievement in this week’s issue of Science Express, the early online edition of the journal Science…
The treatment exploits a novel link, identified by the scientists, between sugar processing in the cells and their growth and division. This approach to treating breast cancer offers a real alternative to chemotherapy as it targets the active cancer cells and not normal cells, reducing the risk of side effects that affect thousands of women undergoing treatment. Breast Cancer Campaign funded scientist, Dr Jeremy Blaydes at the University of Southampton, has shown for the first time that chemicals called cyclic peptide inhibitors can stop ‘sweet toothed’ cancer cells from growing and multiplying by blocking proteins in the cells called CtBPs (C-terminal binding proteins). …
In experiments on zebrafish, Freiburg researchers have demonstrated that the same proteins that lead to the formation of metastases in humans also cause the cells to migrate during embryonic development. The study was conducted by a team headed by Prof. Dr. Wolfgang Driever and Prof. …
The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels. …
The findings are published in the latest issue of the journal Nature Genetics. Brain cancer is the primary cause of cancer mortality in children. Even in cases when the cancer is cured, young patients suffer from the stress of a treatment that can be harmful to the developing brain. In a search for new target structures that would create more gentle treatments, cancer researchers are systematically analyzing all alterations in the genetic material of these tumors…
"Heart failure patients are not only at an increased risk for developing cancer, but the occurrence of cancer increases mortality in these patients," explained Dr. Veronique Roger, MD, director of the Mayo Clinic Center for the Science of Health Care Delivery and co-author of the study. …
Case numbers in Africa's meningitis season this year were the lowest in 10 years thanks to a cheap new vaccine designed to treat a type of the disease common in the so-called meningitis belt, the World Health Organization said on Thursday. The vaccine, called MenAfriVac, was developed with funding from the Bill & Melinda Gates Foundation specifically for use against meningitis A, a type which causes regular epidemics in Africa. Detailing data for January 1 to May 12, the United Nations health agency said that just under 9,250 meningitis cases, including 857 deaths, were reported in 18 of the 19 African countries under enhanced surveillance for meningitis. Epidemics of meningitis A occur regularly in Africa's “meningitis belt”, a band of 26 countries stretching from Senegal to Ethiopia, and are particularly devastating to children and young adults. Bacterial meningitis, known as meningococcal meningitis, is a serious infection of the thin lining surrounding the brain and spinal cord. It can cause severe brain damage and is fatal in 50 percent of cases if untreated. According to the non-profit Meningitis Vaccine Project (MVP), which helped develop the MenAfriVac vaccine, the seasonal outbreak of meningitis across sub-Saharan Africa in 2009 infected at least 88,000 people and killed more than 5,000. The WHO said the falling numbers this year were due to the introduction of the newly developed vaccine. MenAfriVac costs just 50 U.S. cents a dose and has been progressively introduced in Africa since 2010, starting in Burkina Faso, Mali and Niger. “The introduction of this first meningococcal vaccine available for preventive purposes in Africa has enabled the immunization of over 100 million people from 10 countries in the meningitis belt in the past three years,” the WHO said. “The reduced case load and epidemic activity observed this year adds to the evidence on the impact...of this vaccine.”source : http://www.foxnews.com/health/2013/06/07/new-vaccine-drives-africa-meningitis-cases-to-lowest-in-decade/